CCL2 and urinary bladder cancer: The CCL2-neutralizing antibody dramatically decreased the burden of the tumors formed by LNMAT1-transduced cells in the LNs, which led to prolonged survival times in the tumor-bearing nude mice, suggesting that the CCL2 blockade exerted promising anti-tumor effects in LNMAT1-overexpressing bladder cancer by inhibiting LN metastasis.